The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | HMAs or chemotherapy with venetoclax and gilteritinib for FLT3-mutated AML
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, presents a single-center real-world analysis evaluating hypomethylating agent (HMA)- or chemotherapy-based regimens combined with venetoclax and gilteritinib in patients with FLT3-mutated acute myeloid leukemia (AML). The study demonstrated a 95% overall response rate (ORR) and a cumulative complete remission and complete remission with incomplete platelet recovery rate (CR/CRp) of 82%, with rapid responses and a manageable safety profile. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
